pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Zymeworks Inc. ($ZYME) · news · pharmadog
← back to Zymeworks Inc.
News mentioning $ZYME
8
stories
27d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
Oct 11, 26
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
endpoints
Oct 1, 26
Q&A: Anthropic's life sciences team talks Claude's first scientific discovery
endpoints
Aug 7, 26
BioMarin discontinues rare disease drug; CSL and Arcturus split up
endpoints
Aug 6, 26
Intellia identifies genetic risk factor for liver complications in CRISPR trial
endpoints
Jul 1, 26
FDA warns Genzyme's Irish site over quality questions
endpoints
Jun 30, 26
Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe disease
endpoints
May 19, 26
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
endpoints